This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Our Pipeline

We are developing a deep and robust pipeline including late-stage programs with differentiated approaches to clinically validated targets and early-stage novel programs. Our programs are designed to address a range of cancers such as neuroendocrine tumors (“NETs”), prostate cancer, glioblastomas, folate receptor α (“FRα”)-positive tumors, such as ovarian cancer, or non-small cell lung (“NSCL”) adenocarcinoma and clear-cell renal cell
carcinoma (“ccRCC”).

Our programs are designed to address a range of conditions such as neuroendocrine tumors (“NETs”), prostate cancer, glioblastomas, folate receptor α (“FRα”)-positive tumors, such as ovarian cancer or non-small cell lung (“NSCL”) adenocarcinoma, and clear-cell renal cell carcinoma (“ccRCC”).